Chemokine Osteoimmunity and Bone Remodeling: A Survey

Abstract

The intricate interplay between chemokines, particularly the CXCL family, and their role in osteoimmunity is pivotal in regulating immune responses and bone remodeling processes. This survey paper provides a comprehensive analysis of the CXCL chemokine family's influence on skeletal health, emphasizing their dual role in physiological and pathological conditions. Chemokines orchestrate immune cell migration and activation, significantly impacting bone remodeling and inflammatory responses. The study highlights the role of CXCL chemokines in inflammatory bone diseases, such as rheumatoid arthritis, where they modulate osteoclast and osteoblast activity, contributing to disease pathogenesis. Advanced computational models and imaging techniques have enhanced our understanding of these processes, revealing potential therapeutic targets within chemokine signaling pathways. The paper explores the clinical implications of chemokine-mediated interactions, advocating for targeted therapies that modulate inflammatory responses to improve bone health. Future research directions include elucidating the molecular mechanisms underlying chemokine activity and developing innovative therapeutic approaches that integrate bioengineering solutions. By advancing our understanding of chemokine-immune system interactions, this survey aims to inform the development of targeted interventions for bone-related diseases, ultimately enhancing patient outcomes and skeletal health.

1 Introduction

1.1 Overview of Chemokines and Osteoimmunity

Chemokines, a specialized subset of cytokines, are essential for regulating immune cell migration and positioning, thereby influencing immune responses and their interactions with various physiological systems, including the skeletal system [1]. Osteoimmunology investigates these interactions, focusing on the communication between immune cells and bone cells to maintain skeletal integrity and respond to pathological conditions [2]. The CXCL chemokine family is particularly significant due to its dual role in modulating immune responses and bone remodeling processes. This survey elucidates the interplay between the immune system and bone physiology, addressing knowledge gaps in osteoimmunology and its implications for inflammatory diseases [3].

In inflammatory bone diseases like rheumatoid arthritis, chemokines are crucial for modulating inflammatory responses and influencing osteoclast and osteoblast activity, which contributes to disease pathogenesis. Understanding these modulations is vital for elucidating the mechanisms underlying these diseases and developing targeted therapeutic strategies [4]. Moreover, chemokines play a role in physiological bone remodeling, including osseointegration in oral implants, where they interact with various cell types such as macrophages and bone-forming cells. This underscores their importance in health and disease, highlighting the complex interplay between chemokines and the immune-skeletal axis [5].



Figure 1: chapter structure

Recent studies have highlighted the impact of hypoxia on CXC chemokine expression and receptor activity, which may further influence immune cell recruitment within the bone microenvironment. Additionally, extracellular vesicles (EVs) have been identified as critical components in chemokine-mediated communication, particularly in the interactions among mesenchymal stem cells, osteoblasts, and monocyte-macrophage lineages [6].

Investigating chemokines within the osteoimmunology framework enhances our understanding of the intricate interactions between bone and immune systems, particularly the roles of various immune cell types, including T helper cells and macrophages, in bone homeostasis and pathology. This knowledge paves the way for developing targeted therapeutic strategies for treating bone-related diseases such as osteoporosis, rheumatoid arthritis, and osteoarthritis, which are characterized by inflammatory processes adversely affecting bone integrity [7, 3, 8, 2].

1.2 Structure of the Survey

This survey is structured to provide a comprehensive understanding of the role of chemokines, particularly the CXCL family, in osteoimmunity and bone remodeling. It highlights their influence on the differentiation and function of osteoclasts and osteoblasts, as well as their involvement in regulatory mechanisms governing bone formation and resorption under both physiological and pathological conditions [8, 9, 2]. The paper begins with an introduction to chemokines and their significance in osteoimmunity, setting the stage for a detailed exploration of their biological roles.

Following the introduction, the survey delves into the background and definitions, elucidating key concepts such as chemokines, osteoimmunity, and inflammation, which are critical for understanding their impact on skeletal health. The subsequent section focuses on the specific role of CXCL chemokines in osteoimmunity, examining their interactions with immune cells and their influence

AI-generated, for reference only.

on bone health. An analysis of the mechanisms involved in bone remodeling follows, emphasizing cellular dynamics and chemokine-mediated immune regulation.

The survey then addresses the relationship between inflammation and bone health, discussing how chronic inflammation can lead to bone diseases and the involvement of chemokines in these processes. In the penultimate section, clinical implications and potential therapeutic strategies are explored, offering insights into how understanding chemokine-mediated interactions can inform treatment approaches for bone-related diseases. The conclusion synthesizes key findings and suggests future research directions, emphasizing the need for further investigation into the complex interactions between chemokines, immune responses, and bone remodeling. Throughout the survey, the categorization of chemokines and their receptors, particularly regarding leukocyte migration and inflammation in rheumatoid arthritis, is highlighted to underscore their multifaceted roles [10].The following sections are organized as shown in Figure 1.

2 Background and Definitions

2.1 Chemokines and the CXCL Family

The CXCL chemokine family, distinguished by the C-X-C motif, is pivotal in immune modulation and bone remodeling, facilitating osteoimmunological interactions essential for skeletal homeostasis [11, 2]. These chemokines are integral to osteoclastogenesis and macrophage polarization, influencing bone metabolism and remodeling processes. In osteoimmunity, CXCL chemokines modulate the inflammatory response to biomaterial implantation, affecting cytokine release and bone regeneration [8, 12]. CXCL-10, for instance, plays a pro-inflammatory role, contributing to cytokine networks impacting bone health [13]. The chemotaxis of immune cells, particularly through CXCL9–11 and CXCR3, underscores their critical role in type 1 immunity [14].

CXCL chemokines also influence pathological conditions like tumor growth, metastasis, and angiogenesis, shaping the tumor immune landscape and modulating progression [15, 5]. Their involvement extends to tissue regeneration and diseases such as cancer, with receptors like CXCR4 being significant. Extracellular vesicles from mesenchymal stem cells further highlight the importance of CXCL chemokines in bone diseases [6]. The CXCL family is essential for immune response regulation and bone remodeling, forming a fundamental component of the osteoimmune environment. This interplay is central to osteoimmunology, exploring immune-skeletal communication to influence bone health and disease [16, 2, 8, 9, 7].

2.2 Osteoimmunity and Immune Response

Osteoimmunity describes the dynamic relationship between the immune system and bone tissue, crucial for skeletal integrity and remodeling. This balance of pro- and anti-inflammatory signals from immune cells and cytokines is vital for bone remodeling and repair [2]. Disruption can lead to conditions like osteoporosis, characterized by increased osteoclast activity and decreased osteoblast function [3]. Macrophages, polarizing into M1 or M2 states, significantly influence remodeling outcomes, with M1 polarization enhancing inflammatory responses in diseases like periodontitis [3]. CXCL family chemokines mediate immune cell recruitment and activation, central to inflammatory responses in arthritis, facilitating immune cell migration to inflammation sites [2].

Osseointegration is now recognized as an osteoimmune reaction, emphasizing immune responses' role in biomaterials' clinical success for bone regeneration [17]. Biomaterials must minimize adverse inflammatory reactions, as their physicochemical properties influence the inflammatory response and osteogenic differentiation [3]. The immune-bone tissue interplay is also critical during fracture healing, requiring finely tuned immune responses for successful repair. Challenges persist, as many rheumatoid arthritis patients do not respond to biological therapies targeting inflammatory cytokines, highlighting the need for a deeper understanding of osteoimmune mechanisms [3]. Osteoimmunity is a critical axis in bone health, requiring precise immune responses to support bone integrity and function.

2.3 Bone Remodeling Processes

Bone remodeling is a dynamic process essential for skeletal integrity, involving osteoclasts, osteoblasts, and osteocytes. It ensures the replacement of old or damaged bone with new tissue, adapting the skeleton to mechanical demands and repairing micro-damages [18]. Osteoclasts resorb bone, followed by osteoblasts synthesizing new matrix, maintaining balance for bone health. Osteocytes, acting as mechanosensors, regulate osteoclast and osteoblast activities, translating mechanical load into biochemical signals crucial for bone mass modulation [19, 18]. Pathological conditions like osteoporosis and multiple myeloma disrupt this balance, leading to increased resorption and decreased formation [4, 20].

Advancements in imaging, such as lanthanide-doped nanoparticles, enhance visualization of bone remodeling processes, providing insights into bone diseases' spatial and temporal dynamics [21]. Understanding these dynamics is vital for developing therapeutic strategies to restore remodeling balance, particularly in diseases impairing bone quality [22]. The complexity of interactions and the molecular mechanisms mediating these processes remain primary challenges [2]. Bone remodeling is a multifaceted process regulated by cellular interactions, mechanical forces, and biochemical signals, crucial for skeletal health. Disruptions can lead to significant pathologies, underscoring the need for ongoing research to identify new therapeutic strategies and improve outcomes [23, 6, 2, 3, 19].

2.4 Inflammation and Its Biological Roles

Inflammation is a critical biological response, defending against harmful stimuli, including pathogens and irritants, involving immune cell activation and cytokine release to eliminate cell injury causes, clear necrotic cells, and initiate repair [24]. In bone health, inflammation acts as a protective mechanism for repair but can contribute to pathologies when dysregulated. Acute inflammation is essential for pathogen clearance and repair, but chronic inflammation disrupts remodeling, contributing to diseases like osteoporosis and rheumatoid arthritis. This chronic state often involves an imbalance in cytokine production, including TNF and IL-6, affecting osteoclast and osteoblast differentiation, leading to resorption over formation [25].

Inflammation's impact on bone health is evident in biomaterial implantation, where immune reactions can hinder integration [17]. Inflammatory chemokines, such as CXCL-10, recruit inflammatory cells and promote angiogenesis during healing. 'Inflammaging,' chronic low-grade inflammation associated with aging, poses a significant risk for morbidity, affecting bone health and other systems [26]. Long-term immunodeficiency increases conditions like lymphoma risk, emphasizing inflammation's intricate relationship with systemic health [27]. Understanding inflammation mechanisms and effects on bone health is crucial for developing strategies to modulate responses. Current treatments often fail to address the immune mechanisms underlying bone diseases, highlighting the need for deeper understanding of inflammatory pathways and regulation. Balancing inflammation's beneficial aspects in repair and defense with its potential for chronic damage is an ongoing challenge [25].

In recent years, the role of chemokines in osteoimmunity has garnered significant attention, particularly regarding their multifaceted interactions with immune cells and their implications for therapeutic strategies. Understanding these interactions is crucial for advancing our knowledge of skeletal homeostasis and inflammatory responses. As depicted in Figure 2, the hierarchical structure of CXCL chemokines is illustrated, emphasizing their pivotal roles in modulating inflammation and influencing biomaterial integration. This figure categorizes the key functions and interactions of chemokines, providing a comprehensive overview of their contributions to maintaining skeletal health and their potential in addressing inflammatory diseases. Such visual representations not only enhance our understanding but also facilitate the integration of complex biochemical interactions into a coherent narrative.

3 Role of CXCL Chemokines in Osteoimmunity

3.1 Interplay Between Chemokines and Immune Cells

The CXCL chemokine family plays a pivotal role in osteoimmunity by regulating immune cell dynamics within the bone microenvironment, crucial for both physiological bone remodeling and pathological conditions [11]. These chemokines guide the migration and activation of immune



Figure 2: This figure illustrates the hierarchical structure of the role of CXCL chemokines in osteoimmunity, highlighting their interactions with immune cells, influence on biomaterial integration, and involvement in inflammatory responses. The diagram categorizes key functions and interactions of chemokines in maintaining skeletal homeostasis, modulating inflammation, and contributing to therapeutic strategies for inflammatory diseases.

cells, thereby maintaining skeletal homeostasis. Neutrophils, as primary responders to inflammation, exhibit significant responses to environmental stressors, such as pollutants, as evidenced in zebrafish models [28]. This highlights chemokines' role in modulating immune cell responses to external stimuli.

Within the osteoimmunology framework, chemokines are essential for immune cell recruitment at biomaterial implant sites, influencing the inflammatory response and subsequent tissue integration [29]. This recruitment affects macrophage polarization, with mesoporous bioactive glasses (MBGs) promoting a reparative M2 phenotype over the pro-inflammatory M1 phenotype [12]. Such modulation underscores the potential of chemokine-targeted strategies in bone repair and regeneration.

As illustrated in Figure 3, the hierarchical categorization of chemokine interactions with immune cells reveals their multifaceted roles, interactions with biomaterials, and the importance of predictive models. The CXCL family and syndecans are highlighted for their roles in immune modulation, while the effects of MBGs on osteoimmune sites are noted for their influence on biomaterial interactions. Personalized mathematical models that predict cytokine responses further elucidate the interactions between chemokines and immune responses [30]. These models highlight how cytokine levels influence immune cell recruitment and activity, emphasizing chemokines' roles in shaping immune responses within the bone microenvironment. Additionally, exercise programs can modulate inflammatory biomarkers, including CXCL-10, indicating functional improvement in inflammatory conditions.

The structural and functional roles of syndecans in inflammation reveal their interactions with cytokines and the extracellular matrix, illustrating the complex network of chemokine-mediated immune cell interactions [31]. Biomaterials classified by their immunomodulatory properties highlight the significance of chemokine interactions in macrophage polarization and bone health [25]. Furthermore, the CXCL family contributes to an immunosuppressive microenvironment in gliomas, affecting tumor

progression and treatment responses, thereby underscoring their broader immune regulatory roles [15].

Chemokine and immune cell interactions significantly impact bone health by maintaining skeletal integrity and responding to pathological conditions. Biomarkers like MMP-3, CXCL-13, and C5a enhance our understanding of these interactions, offering valuable indicators of immune activity and vasculitis [32].



Figure 3: This figure illustrates the hierarchical categorization of chemokine interactions with immune cells, focusing on their roles, interactions with biomaterials, and predictive models. The CXCL family and syndecans are highlighted for their roles in immune modulation, while osteoimmune sites and MBG effects are noted for their influence on biomaterial interactions. Additionally, predictive models such as cytokine models and AAV markers are emphasized for their significance in understanding immune responses.

3.2 CXCL Chemokines in Inflammatory Responses

CXCL chemokines are central to inflammatory responses, facilitating the recruitment and activation of immune cells at inflammation sites. Their ability to attract leukocytes, particularly neutrophils, to areas of tissue damage or infection initiates and propagates the inflammatory cascade [33]. CXCL-10 (IP-10) is notably induced by pro-inflammatory cytokines such as TNF and IFN, intensifying immune cell recruitment and inflammatory responses [34].

Macrophage activation dynamics, a critical aspect of inflammation, are better understood through models incorporating the Allee effect, which provide a more accurate depiction of macrophage behavior than traditional models [35]. CXCL chemokines are pivotal in macrophage recruitment and polarization during inflammation, where macrophage activation and cytokine release amplify the inflammatory response, creating a sustaining feedback loop.

In vascular contexts, CXCL chemokines like CXCL-10 and CXCL-9 facilitate IL-6 trans-signaling, enhancing its pro-inflammatory effects in human vascular endothelial cells [36]. This pathway highlights the intricate interplay between chemokines and cytokines in mediating vascular inflammation, with significant implications for inflammatory diseases affecting the cardiovascular system.

The complexity of inflammatory responses necessitates computational models simulating interactions between inflammation and other physiological systems, such as the cardiovascular system [37]. These models are crucial for understanding the systemic effects of inflammation and the role of chemokines in modulating these interactions.

CXCL chemokines are integral to mediating inflammatory responses, influencing immune cell recruitment and activation while interacting with other inflammatory mediators to regulate inflammation. Their critical involvement positions chemokines and their receptors as promising therapeutic targets for inflammatory diseases. Modulating chemokine activity could reduce excessive inflammation and improve clinical outcomes, particularly in conditions like rheumatoid arthritis, where aberrant chemokine signaling contributes to disease progression. This approach could lead to more effective therapies, especially for patients unresponsive to traditional treatments targeting inflammatory cytokines [38, 10, 33].

4 Mechanisms of Bone Remodeling

4.1 Cellular Dynamics in Bone Remodeling

Bone remodeling is a multifaceted process involving the synergistic actions of osteoclasts, osteoblasts, and osteocytes, which collectively ensure skeletal integrity. Osteoclasts mediate bone resorption, a process influenced by mechanical forces and oxidative stress that can disrupt remodeling balance by altering osteoclast and osteoblast activities. Computational models, particularly those using partial differential equations, effectively capture these interactions in pathological conditions like multiple myeloma [20].

Osteoblasts are pivotal for bone formation, synthesizing and mineralizing the bone matrix. Advances in modeling, including ordinary differential equations and mechano-chemo-biological frameworks, have clarified the regulatory mechanisms of osteoblast activity and their interaction with osteoclasts [22]. Biomaterials with immunomodulatory properties that enhance macrophage polarization and angiogenesis further support osteoblast function, promoting bone regeneration [25].

Osteocytes, as the most prevalent cells in bone, act as mechanosensors, translating mechanical loads into biochemical signals that govern osteoclast and osteoblast activities [19]. They are crucial for maintaining bone homeostasis, adapting the skeleton to mechanical demands, and repairing micro-damages over time [18].

Integrating cellular, mechanical, and molecular stimuli into computational models, such as iterative finite element analysis and neural network training, enhances our understanding of bone density evolution and remodeling's multifaceted nature [39]. These multiscale approaches offer insights into the spatial and temporal dynamics of bone remodeling, emphasizing the importance of cellular interactions in maintaining bone health.

Repeated bone remodeling is identified as a source of cellular injuries contributing to lymphoid cancers, highlighting the broader implications of these processes on systemic health [27]. Understanding these cellular dynamics is essential for developing therapeutic strategies to restore bone health in pathological conditions [8].

4.2 Mechanisms of Chemokine-Mediated Immune Regulation

Chemokines orchestrate immune responses significantly impacting bone remodeling by directing immune cell migration, crucial for tissue formation during wound healing [38]. Mechanical forces on bone tissues further complicate the chemokine-immune cell interplay, as mechanical loading influences gene expression and cellular activity in bone cells, highlighting the role of biomechanical stimuli in modulating chemokine activity [18].

Figure 4 illustrates the hierarchical structure of chemokine-mediated immune regulation, categorizing its impact on bone remodeling and disease contexts while emphasizing the role of computational models. Key elements depicted include immune cell migration, the influence of mechanical forces, and the roles of osteoclasts and osteoblasts in bone remodeling. Additionally, the figure highlights prognostic models and chronic inflammation within disease contexts, as well as computational models that simulate macrophage behavior and reaction-diffusion processes.

Advanced computational models, such as those simulating macrophage behavior, provide insights into chemokine-mediated immune regulation [40]. These models elucidate macrophage responses to inflammatory stimuli, showing how chemokines influence immune cell dynamics within the bone microenvironment.

In disease contexts, prognostic models based on CXCL expression predict clinical outcomes and suggest targeted therapies for conditions with aberrant chemokine activity [15]. These models are crucial for identifying therapeutic targets within chemokine signaling pathways.

Chemokines also contribute to chronic inflammation, where cellular senescence through the senescence-associated secretory phenotype (SASP) releases inflammatory cytokines [26]. This chronic state can disrupt normal bone remodeling, emphasizing the need for interventions that modulate chemokine activity to restore balance.

Reaction-diffusion models, such as those studying granuloma formation in tuberculosis, provide insights into immune cell spatial distribution and interactions with pathogens [41]. These models

illuminate the complex spatial dynamics of chemokine-mediated immune regulation across various pathological contexts.

The mechanisms of chemokine-mediated immune regulation are multifaceted, involving signaling pathways and cellular interactions essential for bone health. Understanding how chemokines influence bone remodeling is vital for developing targeted therapeutic strategies to enhance skeletal integrity and address pathological conditions, including inflammation-induced bone loss, osteoporosis, and skeletal metastases [8, 9].



Figure 4: This figure illustrates the hierarchical structure of chemokine-mediated immune regulation, categorizing the impact on bone remodeling, disease contexts, and the role of computational models. Key elements include immune cell migration, mechanical forces, and the roles of osteoclasts and osteoblasts in bone remodeling; prognostic models and chronic inflammation in disease contexts; and computational models like macrophage behavior and reaction-diffusion models.

4.3 Influence of Chemokines and Signaling Pathways

Chemokines modulate signaling pathways integral to bone remodeling, influencing cellular activities and interactions within the bone microenvironment. The interplay between chemokines and signaling molecules orchestrates immune cell recruitment and activation, essential for maintaining skeletal health and responding to pathological conditions. Advanced modeling approaches, such as those by Graham et al., provide spatial representations of bone remodeling processes, capturing intricate interactions among cell populations and their effects on bone geometry [42].

Integrating mechanical stimuli into these models is crucial, as demonstrated by George et al., who developed a multiphysics model to compute mechanobiological stimuli affecting bone remodeling [43]. This model accounts for mechanical loads, cellular activities, and nutrient supplies, emphasizing the dynamic nature of bone remodeling and chemokines' role in modulating these factors. Mechanobiological interactions underscore the significance of mechanical forces in regulating chemokine activity and signaling pathways, vital for bone homeostasis.

In inflammatory signaling, Marcou et al. show how conflicting exogenous signals, like TNF and LPS, converge on a common regulatory molecule, creating a bottleneck effect in the signaling pathway [44]. This bottleneck illustrates the complexity of chemokine-mediated signaling, where multiple pathways converge to regulate immune responses and bone remodeling processes. Understanding these regulatory mechanisms is crucial for developing therapeutic strategies to modulate chemokine activity and restore balance in bone remodeling.

The influence of chemokines on signaling pathways involves a complex integration of mechanical, biochemical, and cellular signals, playing a critical role in physiological and pathological contexts, including wound healing, bone remodeling, and macrophage polarization. These interactions affect cellular behaviors such as migration, proliferation, and differentiation [38, 45, 5, 9, 1]. Understanding these dynamics is essential for orchestrating bone remodeling and identifying potential therapeutic targets for conditions affecting bone health.

5 Inflammation and Its Impact on Bone Health

5.1 Chronic Inflammation and Bone Remodeling

Chronic inflammation disrupts the balance between bone resorption and formation, essential for maintaining skeletal integrity. This disruption is driven by complex cytokine and immune cell interactions, complicating therapeutic development [46]. Inflammation's dual role in conditions like osteoporosis and osteoarthritis exacerbates these challenges [47]. Osteocytes, key mechanosensors, translate mechanical stimuli into signals that regulate osteoclast and osteoblast activities [18]. However, chronic inflammation can skew these pathways, promoting bone resorption, as seen in osteoporosis, where pro-inflammatory cytokines enhance osteoclast activity [27].

Recent studies highlight inflammatory pathways as therapeutic targets to mitigate inflammation's adverse effects on bone remodeling. Compounds like infliximab-abda, which lower TNF levels, show promise in alleviating inflammation [34]. Additionally, biomaterials promoting macrophage development without adverse inflammation offer a promising strategy for bone health [27].

As illustrated in Figure 5, chronic inflammation significantly impacts bone remodeling by highlighting the disrupted balance due to cytokine interactions and osteocyte signaling. This figure also emphasizes potential therapeutic targets such as TNF inhibitors and macrophage biomaterials, while acknowledging the complex challenges posed by inflammatory mechanisms and age-related changes. Despite advancements, understanding chronic inflammation's impact on bone remodeling remains challenging due to the complexity of inflammatory mechanisms and their interactions with other biological systems, such as cancer biology [46]. Age-related immune changes further complicate the management of inflammation-related bone disorders [26].



Figure 5: This figure illustrates the impact of chronic inflammation on bone remodeling, highlighting disrupted balance due to cytokine interactions and osteocyte signaling, potential therapeutic targets like TNF inhibitors and macrophage biomaterials, and complex challenges posed by inflammatory mechanisms and age-related changes.

5.2 Inflammation-Induced Bone Diseases

Inflammation-induced bone diseases, such as rheumatoid arthritis and osteoarthritis, illustrate the detrimental effects of chronic inflammation on bone health, leading to joint destruction and bone erosion [47]. Advances in imaging have improved synovitis detection, facilitating timely interventions [47]. Implants further complicate immune-bone interactions, where immune perturbations can cause bone loss, affecting implant stability [29]. Cancer-related bone diseases highlight the complex relationship between inflammation and bone pathology, where inflammatory and cancer cells create a tumor-promoting microenvironment [48]. Balancing inflammation's protective acute responses with its chronic detrimental effects is crucial, particularly in cancer therapy [46].

Continued research into inflammation's mechanisms and its impact on bone health is essential for developing targeted therapies that manage inflammation while preserving skeletal integrity. This is particularly important in conditions like rheumatoid arthritis and osteoporosis, where immune-bone metabolism interplay is vital for healing [8, 16, 7, 2].

5.3 Interplay Between Inflammation and Metabolic Health

The relationship between inflammation and metabolic health is critical in bone disease pathogenesis, where metabolic alterations exacerbate inflammation and contribute to skeletal deterioration. Chronic inflammation, a hallmark of metabolic disorders like obesity, disrupts bone remodeling through increased pro-inflammatory cytokines [47]. Adipose tissue acts as an endocrine organ, secreting cytokines that promote systemic inflammation, influencing bone metabolism and increasing osteoporosis and osteoarthritis risk. Obesity-related inflammation impacts osteoarthritis, where excess weight's mechanical burden is compounded by inflammation, accelerating joint degeneration [47]. This necessitates strategies addressing both mechanical and inflammatory aspects of obesity-related bone diseases. Metabolic syndrome, characterized by insulin resistance, also promotes inflammation, affecting bone health through altered osteoblast and osteoclast activities.

Emerging research highlights epigenetic modifications and noncoding RNAs in mediating metabolic-inflammatory crosstalk, offering insights into inflammation-induced bone diseases [47]. These findings suggest therapeutic avenues targeting epigenetic regulators and RNA molecules to modulate inflammation and improve metabolic health, benefiting bone integrity. Age-related immune changes exacerbate metabolic dysregulation and inflammatory responses, increasing bone disease susceptibility in the elderly. Understanding the relationships among metabolic health, chronic inflammation, and bone remodeling is essential for developing effective therapies, particularly in metabolic disorders like obesity and diabetes. Recent studies emphasize inflammatory mediators like TNF in disrupting bone homeostasis, highlighting the need for targeted interventions addressing bone loss in conditions like rheumatoid arthritis and periodontitis, considering metabolic factors [23, 22, 49, 19]. Integrating insights from signaling pathways involved in bone remodeling, such as Notch and RBP-J, can identify therapeutic targets to enhance outcomes in bone health and metabolic regulation.

6 Clinical Implications and Therapeutic Strategies

Understanding the intricate relationship between inflammation and bone diseases is crucial for developing effective management strategies. Inflammation significantly contributes to the pathogenesis of conditions such as osteoporosis and rheumatoid arthritis (RA), influencing treatment outcomes. A comprehensive examination of inflammatory processes affecting bone health is essential for identifying targeted interventions and innovative therapeutic modalities.

6.1 Clinical Implications of Inflammation in Bone Diseases

Inflammation plays a central role in the pathogenesis of various bone diseases, including osteoporosis and RA, with significant implications for patient management. Modulating chemokines, particularly within the CXCL family, offers a promising therapeutic avenue, as these pathways exacerbate inflammation and promote bone degradation [11]. However, the complexity of chemokine interactions and immune cell plasticity presents challenges in effectively targeting these axes, necessitating advanced strategies to improve clinical outcomes [11].

In RA, personalized mathematical models have been proposed to optimize patient management by predicting cytokine responses, refining treatment plans, and enhancing therapeutic efficacy [40]. These models could lead to personalized treatments by identifying effective macrophage reprogramming strategies, crucial for mitigating inflammation and promoting bone health [40].

Advanced imaging techniques, such as NIR-II imaging using lanthanide-doped nanoparticles, provide non-invasive, high-resolution diagnostics for bone diseases, facilitating early detection and management of inflammation-related conditions [21]. Additionally, automated assessment models like the Mixed Unet model offer insights into environmental pollutants' impact on bone health, further informing clinical strategies [28].

Targeted therapies, such as infliximab-abda, demonstrate rapid declines in inflammatory markers and significant clinical improvements, underscoring the effectiveness of interventions for severe inflammatory conditions [34]. Moreover, osteoimmunity-regulating biomaterials have shown promise in enhancing bone regeneration by modulating macrophage responses, highlighting their potential for clinical applications [25].

The association of CXCL expression with malignant clinical phenotypes and survival outcomes in glioma patients emphasizes the need for targeted interventions in managing inflammation-related bone disorders [15]. In silico models, such as reaction-diffusion models, provide valuable insights into chemokine-mediated immune response dynamics, enhancing our understanding of clinical implications [41].

The clinical implications of inflammation in bone diseases necessitate targeted interventions addressing immune and skeletal cell interactions. By integrating advanced mathematical modeling, insights from osteoimmunology, and innovative therapeutic strategies, clinicians can significantly enhance treatment efficacy and improve patient outcomes in managing inflammation-related bone disorders such as osteoporosis, RA, and peri-implant inflammatory osteolysis [8, 17, 22].

6.2 Therapeutic Approaches to Mitigate Inflammation

Developing therapeutic strategies to mitigate inflammation in bone-related diseases is crucial due to chronic inflammation's detrimental effects on bone remodeling and skeletal health. Targeting inflammatory pathways, particularly those involving tumor necrosis factor (TNF) and innate immune signaling, offers a promising strategy for managing conditions like osteoporosis and RA. Chronic inflammation disrupts the balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. Recent research highlights the importance of understanding molecular mechanisms underlying these inflammatory processes, including Notch and RBP-J signaling, to develop effective therapeutic interventions aimed at restoring bone health and improving patient quality of life [23, 45, 8].

Innovative approaches to enhancing bone tissue regeneration include using mesoporous bioactive glasses (MBGs), which modulate macrophage polarization by preventing the shift towards a pro-inflammatory M1 phenotype while promoting a reparative M2 phenotype. These bioceramics facilitate bone healing and serve as effective drug delivery systems, allowing localized therapy without adverse inflammatory responses. Studies indicate that MBGs can be employed in various forms and significantly support macrophage development and function, playing a crucial role in osteoimmunomodulation and enhancing bone repair processes [12, 25].

Mathematical modeling of inflammatory dynamics provides insights into inflammation progression and therapeutic intervention outcomes. Such models can guide personalized therapeutic approaches by simulating the effects of different interventions on inflammatory pathways. Three-dimensional ordinary differential equation models effectively simulate acute inflammation dynamics by analyzing pathogen and inflammatory mediator interactions, highlighting critical parameters influencing treatment strategies [40, 30, 50, 51, 22].

Antioxidants have emerged as promising agents for osteoporosis, reducing oxidative stress and inflammation contributing to bone loss. Nutritional strategies incorporating antioxidants may mitigate reactive oxygen species (ROS) effects on bone remodeling by promoting osteoblast differentiation and inhibiting osteoclastogenesis, highlighting the potential of dietary antioxidants in supporting bone health [52, 47, 53].

In cancer, targeting inflammatory pathways enhances chemotherapy efficacy, particularly when combined with immunotherapies. This cross-disciplinary approach in osteoimmunology can advance managing inflammation-related bone diseases by leveraging immune and bone cell interactions to inform novel therapeutic strategies for conditions such as RA and osteoarthritis [16, 2, 47, 8, 7]. Cryo-preservation of hematopoietic stem cells in umbilical cords may mitigate inflammation-induced risks in bone-related diseases [27]. Future research should continue exploring molecular pathways in osteoimmunology to develop targeted therapies that effectively modulate inflammatory responses and improve bone health.

The integration of advanced materials, mathematical modeling, and targeted therapeutic interventions, particularly through harnessing osteoimmunity, shows significant potential for effectively addressing inflammation in bone-related diseases. This multifaceted approach aims to restore bone homeostasis by enhancing natural immune responses and mitigating inflammatory osteolysis, ultimately improving patient outcomes and preserving skeletal integrity [17, 54].

6.3 Molecular Mechanisms and Therapeutic Targets

Elucidating molecular mechanisms and identifying therapeutic targets are pivotal for advancing bone disease treatment. Chemokines, particularly from the CXCL family, are central to immune responses and bone remodeling. CXCL1 and CXCL2 serve as potential biomarkers and therapeutic targets in inflammatory diseases and cancers, underscoring their significance in bone pathology [11]. Regulating osteoclastogenesis through signaling pathways like Notch and RBP-J presents opportunities for therapeutic interventions aimed at controlling inflammation and bone resorption.

Advanced modeling techniques are crucial for understanding complex bone remodeling dynamics, revealing how interactions between osteoblasts, osteoclasts, and signaling molecules like RANKL and OPG can lead to dynamical instabilities. These models highlight the importance of osteoblast precursors in regulating bone remodeling, demonstrating that parameter regimes representative of biological systems are often near bifurcation lines, where small changes can trigger significant shifts in behavior. Proximity to bifurcation facilitates adaptive responses to external stimuli but also poses a risk of losing dynamical stability, linked to conditions such as Paget's disease [51, 55].

To provide a visual representation of these concepts, Figure 6 illustrates the hierarchical structure of molecular mechanisms and therapeutic targets in bone disease treatment, categorizing key signaling pathways, modeling techniques, and therapeutic strategies. This figure serves to enhance our understanding of the intricate relationships among these elements, further emphasizing the complexity of bone disease pathology.

Syndecans have emerged as critical regulators of inflammation, with expression levels and shedding dynamics playing vital roles in controlling the inflammatory response. Targeting syndecans in therapeutic strategies could modulate inflammation in bone diseases. The macrophage-osteoclast axis is crucial in regulating bone resorption and remodeling, significantly impacting osteoimmunity and the pathogenesis of osteo-related diseases. Understanding this interaction could lead to innovative strategies for managing conditions like RA and periodontitis, where chronic inflammation disrupts bone homeostasis [23, 4, 54, 56].

Extracellular vesicles (EVs) play a pivotal role in maintaining bone homeostasis by facilitating essential osteoimmune interactions between mesenchymal stem cells, osteoblasts, and monocytes/macrophages. Their involvement in cell-to-cell communication highlights their potential as innovative therapeutic targets for treating bone diseases, particularly in addressing imbalances that lead to bone loss and impaired healing [6, 54]. Additionally, the role of hypoxia in regulating CXC chemokines is essential for developing targeted cancer therapies.

Future research should focus on identifying biomarkers for inflammation-related cancer risk and developing targeted therapies to modulate inflammatory responses in cancer patients [46]. Targeting pathways related to cell senescence, immune dysregulation, and coagulation factors may offer therapeutic opportunities to mitigate chronic inflammation effects [26].

Understanding molecular mechanisms and identifying therapeutic targets require an integrated approach. By targeting key signaling pathways and immune interactions, strategies can be developed to manage inflammation and promote bone health. Developing integrative models incorporating biological and mechanical factors, alongside a thorough understanding of disease-specific mechanisms, is essential for improving treatment strategies for various bone diseases, such as osteoporosis and Paget's disease [43, 51, 22, 18, 19].

6.4 Innovative Therapeutic Approaches

Emerging therapeutic approaches for treating bone diseases increasingly focus on the interplay between immune responses and bone remodeling processes. Targeted immunomodulatory therapies hold significant promise, particularly in modulating specific immune cell types involved in bone healing. These strategies aim to optimize the immune response, improving osseointegration and mitigating marginal bone loss, essential for the long-term success of bone implants. By leveraging osteoimmunology principles, these approaches enhance the interplay between bone metabolism and immune function, addressing challenges like inflammatory osteolysis arising from infection or systemic conditions [17, 2].

Future research is expected to explore molecular mechanisms underlying immune-bone interactions, potentially uncovering novel therapeutic avenues, such as modulating CXCR4 signaling pathways in



Figure 6: This figure illustrates the hierarchical structure of molecular mechanisms and therapeutic targets in bone disease treatment, categorizing key signaling pathways, modeling techniques, and therapeutic strategies.

regenerative medicine [5]. Additionally, investigating non-canonical functions of signaling pathways like RBP-J and Notch in bone remodeling could unveil new therapeutic targets for inflammatory bone diseases [4]. The microbiome's role in modulating inflammation and its impact on bone health is another promising research area, with implications for developing targeted therapies addressing aging and inflammatory cell death modalities [57].

Identifying relevant chemokine receptors for targeted therapy and exploring combination therapies could enhance treatment efficacy for bone diseases [58]. Current research has identified key chemokines that significantly improve wound healing when targeted appropriately, demonstrating their therapeutic potential and suggesting innovative therapeutic approaches [38]. Future work could focus on identifying specific markers for protumor macrophages and developing therapies that selectively target these cells while preserving their antitumor functions [59].

Innovative approaches also include developing mathematical models to simulate immune dynamics and optimize therapeutic strategies. These models can be refined to incorporate complex immune interactions and evaluate the effects of various therapeutic agents, guiding optimal control strategies for treating bone diseases [60]. Extending these models to two-dimensional domains and investigating higher-order nonlinear effects could provide deeper insights into spatial and temporal immune response dynamics in bone pathology [33].

Furthermore, the link between immune responses and metabolic regulation presents another frontier for novel therapeutic approaches, potentially offering new strategies for managing bone diseases through metabolic pathways [61]. Exploring additional regulatory mechanisms, such as those involving syndecans, could lead to innovative interventions targeting inflammatory diseases [31].

The integration of advanced immunomodulatory therapies, microbiome research, and sophisticated modeling techniques represents a comprehensive approach to developing innovative treatments for bone diseases, paving the way for improved patient outcomes and enhanced skeletal health. Future research should focus on elucidating pro-inflammatory stress molecular pathways, exploring the relationship between inflammation and chronic diseases, and developing therapeutic strategies targeting these processes [62].

6.5 Biomarkers and Diagnostic Tools

Identifying and applying biomarkers and diagnostic tools are crucial for early detection and management of bone health and disease. Biomarkers serve as measurable indicators of physiological and pathological processes, essential for assessing the risk, presence, and progression of bone-related diseases. In osteoimmunology, the CXCL chemokine family has been highlighted as a potential source of biomarkers due to their involvement in immune responses and bone remodeling processes [11]. These chemokines, including CXCL-10, are pivotal in mediating inflammatory responses, making them valuable targets for diagnostic applications in inflammatory bone diseases [33].

Recent advancements in imaging techniques have significantly enhanced diagnostic capabilities for bone health assessment. Near-infrared II (NIR-II) imaging using lanthanide-doped nanoparticles pro-

vides high-resolution, non-invasive diagnostic options, facilitating early-stage bone disease detection [21]. This technology offers a safer alternative to traditional imaging methods, reducing ionizing radiation exposure and improving diagnosis accuracy.

In addition to imaging, personalized mathematical models have provided insights into cytokine responses and their implications for bone health [40]. These models can predict inflammatory biomarker dynamics, aiding in identifying individuals at risk for bone diseases and tailoring therapeutic interventions accordingly.

Integrating machine learning algorithms, such as the Mixed Unet model, has further enhanced the ability to assess environmental impacts on bone health [28]. These models analyze large datasets to identify patterns and predict pollutants' effects on bone integrity, offering a comprehensive approach to bone health assessment.

Biomarkers such as MMP-3, CXCL-13, and C5a have been identified as significant indicators of immune activity and vasculitis, providing valuable information for diagnosing and monitoring bone diseases [32]. These biomarkers are instrumental in understanding complex interactions between the immune system and bone tissue, facilitating targeted diagnostic tool development.

Exploring biomarkers and diagnostic tools in osteoimmunology is vital for advancing the understanding and management of bone health and disease. By integrating cutting-edge imaging techniques, advanced computational models, and molecular biomarkers, clinicians can significantly enhance diagnostic accuracy for various bone disorders, such as osteoporosis and Paget's disease, while tailoring personalized treatment strategies. Recent advancements in computational modeling, including model-checking approaches, allow for assessing bone mineral density and identifying rapid declines in bone health, which can indicate co-morbidity onset. Additionally, mathematical models of bone remodeling and mechanistic pharmacokinetic/pharmacodynamic frameworks facilitate a deeper understanding of complex interactions between bone diseases and treatment effects, ultimately leading to more effective management of bone health [42, 51, 22, 63, 19].

6.6 Clinical Trials and Future Research Directions

Ongoing clinical trials are pivotal in advancing the understanding and treatment of bone-related diseases, particularly those involving the CXCL chemokine family and their role in osteoimmunity. Current trials explore the therapeutic potential of targeting CXCL chemokines in inflammatory bone diseases, focusing on modulating immune responses to improve bone health [64]. These trials aim to translate preclinical findings into clinical applications, assessing the efficacy and safety of novel interventions in human populations.

Future research directions should prioritize elucidating CXCLs' precise roles in disease mechanisms, particularly regarding hypoxia-induced chemokine expression implicated in various pathological conditions [65]. Understanding these pathways could lead to developing targeted therapies mitigating hypoxia's adverse effects on bone health.

Integrating computational models in clinical research presents an opportunity to enhance predictive capabilities and personalize treatment strategies. Refining existing models, such as those used in multiple myeloma, by incorporating additional biological factors and validating them with clinical data will improve their applicability in clinical settings [20]. Reverse engineering from patient datasets and utilizing parametric probabilistic model repair techniques are promising approaches for refining these models [63].

Incorporating biomarkers into routine clinical practice is another critical area for future exploration. Investigating the significance of biomarkers such as MMP-3, CXCL-13, and C5a in treatment decision-making should enhance diagnostic accuracy and tailor therapeutic interventions [32].

Experimental studies using animal models could provide valuable insights into the relationship between bone injuries and the development of conditions such as leukemia, offering a platform for verifying existing hypotheses and exploring new therapeutic avenues [66]. Additionally, developing advanced in vitro models that accurately replicate in vivo conditions will be crucial for studying mechanical loading effects on bone cells and refining therapeutic approaches [18].

Future research should also focus on the regulatory mechanisms of Smad signaling in bone formation and resorption. Clarifying these mechanisms could facilitate developing targeted therapies that

enhance osteoblast activity while inhibiting osteoclast formation, thereby improving bone health outcomes [67].

Integrating bioengineering solutions with therapeutic strategies offers a promising approach to enhance osteoimmunomodulation in clinical settings. By refining these approaches, researchers can develop more effective treatments that improve patient outcomes in bone-related diseases [17].

7 Conclusion

Chemokines, particularly the CXCL family, play a crucial role in orchestrating immune responses and bone remodeling, both of which are vital for maintaining skeletal health and responding to disease. These molecules are instrumental in directing immune cell recruitment, activation, and polarization. The intricacies of inflammatory responses highlight the need for tailored therapeutic strategies that address the variability in inflammation dynamics. Advanced computational models, alongside cutting-edge imaging techniques, have significantly contributed to our understanding of bone remodeling processes, offering insights into the sensitivity of these systems to various parameters and potential pathological scenarios.

Future research should focus on unraveling the complex interactions between chemokines and immune cells within the tumor microenvironment to inform the development of targeted therapies. Additionally, longitudinal studies exploring emodiversity and its influence on inflammation could provide valuable insights into causal mechanisms and potential therapeutic interventions. The utilization of in silico macrophage modeling offers a promising avenue for enhancing our comprehension of macrophage behavior in inflammatory contexts, thereby supporting the formulation of precise therapeutic approaches. Moreover, further investigation into the mechanisms of cell transformation in lymphoid cells is necessary to elucidate the links between cellular injuries and the onset of lymphoid cancers.

References

[1] Pieter Ruytinx, Paul Proost, Jo Van Damme, and Sofie Struyf. Chemokine-induced macrophage polarization in inflammatory conditions. *Frontiers in immunology*, 9:1930, 2018.

[2] Hiroshi Takayanagi. Osteoimmunology—bidirectional dialogue and inevitable union of the fields of bone and immunity—. *Proceedings of the Japan Academy, Series B*, 96(4):159–169, 2020.

[3] Claudine Blin-Wakkach and Teun J de Vries. Advances in osteoimmunology, 2019.

[4] Yao Yao, Xiaoyu Cai, Fujia Ren, Yiqing Ye, Fengmei Wang, Caihong Zheng, Ying Qian, and Meng Zhang. The macrophage-osteoclast axis in osteoimmunity and osteo-related diseases. *Frontiers in Immunology*, 12:664871, 2021.

[5] Marco E Bianchi and Rosanna Mezzapelle. The chemokine receptor cxcr4 in cell proliferation and tissue regeneration. *Frontiers in Immunology*, 11:2109, 2020.

[6] Xiaoyuan Huang, Yanhua Lan, Jiahui Shen, Zhuo Chen, and Zhijian Xie. Extracellular vesicles in bone homeostasis: emerging mediators of osteoimmune interactions and promising therapeutic targets. *International Journal of Biological Sciences*, 18(10):4088, 2022.

[7] Hamid Y Dar, Zaffar Azam, Rajaneesh Anupam, Rajesh K Mondal, Rupesh K Srivastava, et al. Osteoimmunology: The nexus between bone and immune system. *Front Biosci (Landmark Ed)*, 23(3):464–492, 2018.

[8] Matthew C Walsh, Noriko Takegahara, Hyunsoo Kim, and Yongwon Choi. Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity. *Nature Reviews Rheumatology*, 14(3):146–156, 2018.

[9] Laura J Brylka and Thorsten Schinke. Chemokines in physiological and pathological bone remodeling. *Frontiers in immunology*, 10:2182, 2019.

[10] Masanori A Murayama, Jun Shimizu, Chie Miyabe, Kazuo Yudo, and Yoshishige Miyabe. Chemokines and chemokine receptors as promising targets in rheumatoid arthritis. *Frontiers in Immunology*, 14:1100869, 2023.

[11] Katharina Helene Susek, Maria Karvouni, Evren Alici, and Andreas Lundqvist. The role of cxc chemokine receptors 1–4 on immune cells in the tumor microenvironment. *Frontiers in immunology*, 9:2159, 2018.

[12] M. J. Feito, L. Casarrubios, M. Onaderra, M. Gomez-Duro, P. Arribas, A. Polo-Montalvo, M. Vallet-Regi, D. Arcos, and M. T. Portoles. Response of raw 264.7 and j774a.1 macrophages to particles and nanoparticles of a mesoporous bioactive glass: A comparative study", 2021.

[13] Anuradha S Tripathy, Siddhesh Vishwakarma, Diptee Trimbake, Yogesh K Gurav, Varsha A Potdar, Nitin D Mokashi, Sudhir D Patsute, Himanshu Kaushal, Manohar L Choudhary, Bipin N Tilekar, et al. Pro-inflammatory cxcl-10, tnf-α, il-1β, and il-6: biomarkers of sars-cov-2 infection. *Archives of Virology*, 166:3301–3310, 2021.

[14] Haizhan Jiao, Bin Pang, Aijun Liu, Qiang Chen, Qi Pan, Xiankun Wang, Yunong Xu, Ying-Chih Chiang, Ruobing Ren, and Hongli Hu. Structural insights into the activation and inhibition of cxc chemokine receptor 3. *Nature Structural & Molecular Biology*, 31(4):610–620, 2024.

[15] Zeyu Wang, Yuze Liu, Yuyao Mo, Hao Zhang, Ziyu Dai, Xun Zhang, Weijie Ye, Hui Cao, Zhixiong Liu, and Quan Cheng. The cxcl family contributes to immunosuppressive microenvironment in gliomas and assists in gliomas chemotherapy. *Frontiers in immunology*, 12:731751, 2021.

[16] Rayan Ben Letaifa, Tarek Klaylat, Magdalena Tarchala, Chan Gao, Prism Schneider, Derek H Rosenzweig, Paul A Martineau, and Rahul Gawri. Osteoimmunology: An overview of the interplay of the immune system and the bone tissue in fracture healing. *Surgeries*, 5(2):402–414, 2024.

[17] Zijun Chen, Yuxi Wang, Rui Yang, Xiangdong Liu, Guanhua Zhang, Qun Lu, Wei Ma, and Yingliang Song. Harnessing osteoimmunity to treat peri-implant inflammatory osteolysis. *Materials Advances*, 5(8):3113–3134, 2024.

[18] Lijun Wang, Xiuling You, Lingli Zhang, Changqing Zhang, and Weiguo Zou. Mechanical regulation of bone remodeling. *Bone research*, 10(1):16, 2022.

[19] Simona Bolamperti, Isabella Villa, and Alessandro Rubinacci. Bone remodeling: an operational process ensuring survival and bone mechanical competence. *Bone Research*, 10(1):48, 2022.

[20] Catherine E. Patterson, Bruce P. Ayati, and Sarah A. Holstein. Modeling the multiple myeloma vicious cycle: Signaling across the bone marrow microenvironment, 2015.

[21] Chao Mi, Xun Zhang, Chengyu Yang, Jianqun Wu, Xinxin Chen, Chenguang Ma, Sitong Wu, Zhichao Yang, Pengzhen Qiao, Yang Liu, Weijie Wu, Zhiyong Guo, Jiayan Liao, Jiajia Zhou, Ming Guan, Chao Liang, Chao Liu, and Dayong Jin. Nanoparticles passive targeting allows optical imaging of bone diseases, 2023.

[22] Imane Ait Oumghar, Abdelwahed Barkaoui, and Patrick Chabrand. Toward a mathematical modeling of diseases' impact on bone remodeling: technical review. *Frontiers in bioengineering and biotechnology*, 8:584198, 2020.

[23] Baohong Zhao. Tnf and bone remodeling. *Current osteoporosis reports*, 15:126–134, 2017.

[24] Linlin Chen, Huidan Deng, Hengmin Cui, Jing Fang, Zhicai Zuo, Junliang Deng, Yinglun Li, Xun Wang, and Ling Zhao. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*, 9(6):7204, 2017.

[25] Zongtai Liu, Jin Zhang, Changfeng Fu, and Jianxun Ding. Osteoimmunity-regulating biomaterials promote bone regeneration. *Asian Journal of Pharmaceutical Sciences*, 18(1):100774, 2023.

[26] Fumihiro Sanada, Yoshiaki Taniyama, Jun Muratsu, Rei Otsu, Hideo Shimizu, Hiromi Rakugi, and Ryuichi Morishita. Source of chronic inflammation in aging. *Frontiers in cardiovascular medicine*, 5:12, 2018.

[27] Jicun Wang-Michelitsch and Thomas M Michelitsch. Three potential sources of cell injuries of lymphoid cells associated with developments of lymphoid leukemia and lymphoma, 2018.

[28] Lulu Xu, Peiwu Qin, Zhenglin Chen, and Jiaqi Yang. Deep learning enables automated assessments of inflammatory response in zebrafish exposed to different pollutants, 2024.

[29] Tomas Albrektsson, Pentti Tengvall, L Amengual, Pierluigi Coli, GA Kotsakis, and D Cochran. Osteoimmune regulation underlies oral implant osseointegration and its perturbation. *Frontiers in immunology*, 13:1056914, 2023.

[30] Renee Brady, Dennis O. Frank-Ito, Hien T. Tran, Susanne Janum, Kirsten Møller, Susanne Brix, Johnny T. Ottesen, Jesper Mehlsen, and Mette S. Olufsen. Personalized mathematical model predicting endotoxin-induced inflammatory responses in young men, 2016.

[31] Sandeep Gopal. Syndecans in inflammation at a glance. *Frontiers in immunology*, 11:227, 2020.

[32] Aleksandra Rymarz, Magdalena Mosakowska, and Stanisław Niemczyk. The significance of metalloproteinase 3 (mmp-3), chemokine cxc ligand 13 (cxcl-13) and complement component c5a in different stages of anca associated vasculitis. *Scientific reports*, 11(1):5132, 2021.

[33] LA Abdulkhaleq, MA Assi, Rasedee Abdullah, M Zamri-Saad, YH Taufiq-Yap, and MNM Hezmee. The crucial roles of inflammatory mediators in inflammation: A review. *Veterinary world*, 11(5):627, 2018.

[34] Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann, Christian Lawlor, Jill Marshall, Andreas Klein, Debra Poutsiaka, Janis L Breeze, et al. Rapid and sustained decline in cxcl-10 (ip-10) annotates clinical outcomes following tnfα-antagonist therapy in hospitalized patients with severe and critical covid-19 respiratory failure. *Journal of Clinical and Translational Science*, 5(1):e146, 2021.

[35] Marzia Bisi, Maria Groppi, Giorgio Martalò, and Cinzia Soresina. A chemotaxis reaction-diffusion model for multiple sclerosis with allee effect, 2023.

[36] Mulugeta M Zegeye, Madelene Lindkvist, Knut Fälker, Ashok K Kumawat, Geena Paramel, Magnus Grenegård, Allan Sirsjö, and Liza U Ljungberg. Activation of the jak/stat3 and pi3k/akt pathways are crucial for il-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. *Cell Communication and Signaling*, 16:1–10, 2018.

[37] Atanaska Dobreva, Renee Brady, Kamila Larripa, Charles Puelz, Jesper Mehlsen, and Mette S. Olufsen. A physiological model of the inflammatory-thermal-pain-cardiovascular interactions during a pathogen challenge, 2019.

[38] Anisyah Ridiandries, Joanne TM Tan, and Christina A Bursill. The role of chemokines in wound healing. *International journal of molecular sciences*, 19(10):3217, 2018.

[39] Ridha Hambli and Abdelwahed Barkaoui. Multiscale approach for bone remodeling simulation based on finite element and neural network computation, 2011.

[40] Peter Ghazal, Steven Watterson, Kevin Robertson, and David C Kluth. The in silico macrophage: toward a better understanding of inflammatory disease, 2011.

[41] C. Accarino, R. Accarino, F. Capone, R. De Luca, L. Fiorentino, and G. Massa. A reaction-diffusion model for mycobacterium tuberculosis infection, 2024.

[42] Jason M. Graham, Bruce P. Ayati, Prem S. Ramakrishnan, and James A. Martin. Towards a new spatial representation of bone remodeling, 2012.

[43] Daniel George, Rachele Allena, and Yves Remond. A multiphysics stimulus for continuum mechanics bone remodeling. *Mathematics and Mechanics of Complex Systems*, 6(4):307–319, 2018.

[44] Quentin Marcou, Irit Carmi-Levy, Coline Trichot, Vassili Soumelis, Thierry Mora, and Aleksandra M. Walczak. A model for the integration of conflicting exogenous and endogenous signals by dendritic cells, 2016.

[45] Xia Li, Chentao Li, Wanying Zhang, Yanan Wang, Pengxu Qian, and He Huang. Inflammation and aging: signaling pathways and intervention therapies. *Signal transduction and targeted therapy*, 8(1):239, 2023.

[46] A Korniluk, O Koper, H Kemona, and V Dymicka-Piekarska. From inflammation to cancer. *Irish Journal of Medical Science (1971-)*, 186:57–62, 2017.

[47] Carla R Scanzello. Role of low-grade inflammation in osteoarthritis. *Current opinion in rheumatology*, 29(1):79–85, 2017.

[48] Lance L Munn. Cancer and inflammation. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, 9(2):e1370, 2017.

[49] Gökhan S Hotamisligil. Inflammation, metaflammation and immunometabolic disorders. *Nature*, 542(7640):177–185, 2017.

[50] Rukmini Kumar, Gilles Clermont, Yoram Vodovotz, and Carson Chow. Dynamics of acute inflammation, 2004.

[51] Martin Zumsande, Dirk Stiefs, Stefan Siegmund, and Thilo Gross. General analysis of mathematical models for bone remodeling, 2010.

[52] Zaffar Azam, Leena Sapra, Kalpana Baghel, Niharika Sinha, Rajesh K Gupta, Vandana Soni, Chaman Saini, Pradyumna K Mishra, and Rupesh K Srivastava. Cissus quadrangularis (hadjod) inhibits rankl-induced osteoclastogenesis and augments bone health in an estrogen-deficient preclinical model of osteoporosis via modulating the host osteoimmune system. *Cells*, 12(2):216, 2023.

[53] Vladana Domazetovic, Gemma Marcucci, Teresa Iantomasi, Maria Luisa Brandi, and Maria Teresa Vincenzini. Oxidative stress in bone remodeling: role of antioxidants. *Clinical Cases in Mineral and Bone Metabolism*, 14(2):209, 2017.

[54] Jason M. Graham, Bruce P. Ayati, Sarah A. Holstein, and James A. Martin. The role of osteocytes in targeted bone remodeling: A mathematical model, 2013.

[55] Marc Ryser, Svetlana V. Komarova, and Nilima Nigam. The cellular dynamics of bone remodeling: a mathematical model, 2011.

[56] Brendan F Boyce, Jinbo Li, Lianping Xing, and Zhenqiang Yao. Bone remodeling and the role of traf3 in osteoclastic bone resorption. *Frontiers in immunology*, 9:2263, 2018.

[57] Mihai G Netea, Frances Balkwill, Michel Chonchol, Fabio Cominelli, Marc Y Donath, Evangelos J Giamarellos-Bourboulis, Douglas Golenbock, Mark S Gresnigt, Michael T Heneka, Hal M Hoffman, et al. A guiding map for inflammation. *Nature immunology*, 18(8):826–831, 2017.

[58] Xuyan Chen, Renpin Chen, Ruifang Jin, and Zhiming Huang. The role of cxcl chemokine family in the development and progression of gastric cancer. *International journal of clinical and experimental pathology*, 13(3):484, 2020.

[59] Alberto Mantovani. The inflammation–cancer connection. *The FEBS journal*, 285(4):638, 2018.

[60] Amit K Goyal, Manish Ramchandani, and Trambak Basak. Recent advancements, challenges, and future prospects in usage of nanoformulation as theranostics in inflammatory diseases. *Journal of Nanotheranostics*, 4(1):106–126, 2023.

[61] Diego Marcos-Pérez, Sara Cruces-Salguero, Esther García-Domínguez, Marcos J Araúzo-Bravo, Mari Carmen Gómez-Cabrera, José Viña, Itziar Vergara, and Ander Matheu. Physical interventions restore physical frailty and the expression of cxcl-10 and il-1β inflammatory biomarkers in old individuals and mice. *Biomolecules*, 14(2):166, 2024.

[62] Evgenii Gusev and Yulia Zhuravleva. Inflammation: A new look at an old problem. *International Journal of Molecular Sciences*, 23(9):4596, 2022.

[63] Pietro Liò, Emanuela Merelli, and Nicola Paoletti. Multiple verification in computational modeling of bone pathologies, 2011.

[64] Chenjia Zhou, Ying Gao, Peilun Ding, Tao Wu, and Guang Ji. The role of cxcl family members in different diseases. *Cell Death Discovery*, 9(1):212, 2023.

[65] Jan Korbecki, Klaudyna Kojder, Patrycja Kapczuk, Patrycja Kupnicka, Barbara Gawrońska-Szklarz, Izabela Gutowska, Dariusz Chlubek, and Irena Baranowska-Bosiacka. The effect of hypoxia on the expression of cxc chemokines and cxc chemokine receptors—a review of literature. *International journal of molecular sciences*, 22(2):843, 2021.

[66] Jicun Wang-Michelitsch and Thomas M Michelitsch. Acute lymphoblastic leukemia may develop as a result of rapid transformation of a lymphoblast triggered by repeated bone-remodeling during bone-growth, 2018.

[67] Ming-Li Zou, Zhong-Hua Chen, Ying-Ying Teng, Si-Yu Liu, Yuan Jia, Kai-Wen Zhang, Zi-Li Sun, Jun-Jie Wu, Zheng-Dong Yuan, Yi Feng, et al. The smad dependent tgf-β and bmp signaling pathway in bone remodeling and therapies. *Frontiers in molecular biosciences*, 8:593310, 2021.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.